Novo Nordisk can add data showing Tresiba can reduce the risk of hypoglycaemia to its label, a development which should help its fight competition from cheaper alternatives. The FDA has ruled that ...

Novo Nordisk’s strong intangible assets in diabetes ... and Novo could achieve a strong share in these nascent markets. Tresiba’s strong profile in the long-acting insulin market hasn ...

Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity and diabetes drug, the company announced March 24. The drug ...

https://www.tipranks.com/news/the-fly/novo-nordisk-warns-of-counterfeit-ozempic-injections Novo Nordisk (NVO) said it has become aware of several hundred units of ...

Novo Nordisk has beaten Wall Street's revenue estimates ... [$7.09] due to my more optimistic sales expectations for Tresiba, Sogroya, Wegovy, NovoSeven, and Ozempic, as well as the launches ...

Novo Nordisk (NVO) has become aware of several hundred units of Ozempic injection 1 mg distributed outside the Novo Nordisk authorized supply chain in the U.S., the company announced. The Food and ...